Organic compounds -- part of the class 532-570 series – Organic compounds – Pteroyl per se or having -c- – wherein x is chalcogen – bonded...
Reexamination Certificate
2000-05-15
2003-02-11
Shah, Mukund J. (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Pteroyl per se or having -c-, wherein x is chalcogen, bonded...
C544S265000, C544S266000, C544S267000, C544S268000, C544S269000, C544S270000, C544S271000, C544S272000, C544S273000, C544S274000, C544S275000, C544S276000, C544S277000, C544S297000, C544S298000, C544S299000, C544S300000, C544S301000, C544S302000, C544S303000, C544S304000, C544S305000, C544S306000, C544S307000, C544S308000, C544S309000, C544S310000, C544S311000, C544S312000, C544S313000, C544S314000, C544S315000, C544S316000, C544S317000, C544S318000, C544S319000, C544S320000, C544S321000, C544S322000, C544S
Reexamination Certificate
active
06518425
ABSTRACT:
BACKGROUND OF THE INVENTION
The success of various synthetic nucleosides such as AZT, D4T, DDI, and DDC in inhibiting the replication of HIV in vivo or in vitro led researchers in the late 1980's to design and test nucleosides that substitute a heteroatom for the carbon atom at the 3′-position of the nucleoside. Norbeck, et al., disclosed that (±)-1-[cis-(2,4)-2-(hydroxymethyl)-4-dioxolanyl]thymine (referred to as (±)-dioxolane-T) exhibits a modest activity against HIV (EC
50
of 20 &mgr;M in ATH8 cells), and is not toxic to uninfected control cells at a concentration of 200 &mgr;M.
Tetrahedron Letters
30 (46), 6246, (1989). European Patent Application Publication No. 337 713 and U.S. Pat. No. 5,041,449, assigned to BioChem Pharma, Inc., disclose racemic 2-substituted-4-substituted-1,3-dioxolanes that exhibit antiviral activity. Published PCT application numbers PCT US91/09124 and PCT US93/08044 disclose isolated &bgr;-D-1,3-dioxolanyl nucleosides for the treatment of HIV infection. WO 94/09793 discloses the use of isolated &bgr;-D-1,3-dioxolanyl nucleosides for the treatment of HBV infection.
Published PCT US95/11464 discloses that (−)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine is useful in the treatment of tumors and other abnormal cell proliferation.
U.S. Pat. No. 5,047,407 and European Patent Application Publication No. 0 382 526, also assigned to BioChem Pharma, Inc., disclose that a number of racemic 2-substituted-5-substituted-1,3-oxathiolane nucleosides have antiviral activity, and specifically report that the racemic mixture of 2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (referred to below as BCH-189) has approximately the same activity against HIV as AZT, with less toxicity. The (−)-enantiomer of BCH-189 (U.S. Pat. No. 5,539,116 to Liotta, et al.), known as 3TC, is now sold commercially for the treatment of HIV in humans in the United States. See also EP 513 200 B1.
It has also been disclosed that cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (“FTC”) has potent HIV activity. See Schinazi, et al., “Selective Inhibition of Human Immunodeficiency viruses by Racemates and Enantiomers of cis-5-Fluoro-1-[2-(Hydroxymethyl)-1,3-Oxathiolane-5-yl]Cytosine”
Antimicrobial Agents and Chemotherapy
, November 1992, page 2423-2431. See also U.S. Pat. Nos. 5,814,639; 5,914,331; 5,210,085; U.S. Pat. No. 5,204,466, WO 91/11186, and WO 92/14743.
Because of the commercial importance of 1,3-oxathiolane nucleosides, a number of processes for their production have been described in patents and scientific literature. Three key aspects of the synthesis must be considered during design of the process. First, the reaction scheme must provide an efficient route to the 1,3-oxathiolane ring structure, preferably, with substituent groups in place for use in subsequent reactions. Second, the reaction scheme must provide an efficient means to condense the 1,3-oxathiolane ring with a suitably protected base, which, in the case of 3TC is cytosine, and in the case of FTC is 5-fluorocytosine. Third, the reaction must be stereoselective, i.e., it must provide the enantiomer of choice. The substituents on the chiral carbons (the specified purine or pyrimidine base (referred to as the C5 substituent) and CH
2
OH (referred to as the C2 substituent)) of the 1,3-oxathiolane nucleosides can be either cis (on the same side) or trans (on opposite sides) with respect to the oxathiolane ring system. Both the cis and trans racemates consist of a pair of optical isomers. Hence, each compound has four individual optical isomers. The four optical isomers are represented by the following configurations (when orienting the oxathiolane moiety in a horizontal plane such that the —S—CH
2
— moiety is in back): (1) cis (also referred to as &bgr;), with both groups “up”, which is the naturally occurring L-cis configuration (2) cis, with both groups “down”, which is the non-naturally occurring &bgr;-cis configuration; (3) trans (also referred to as the &agr;-configuration) with the C2 substituent “up” and the C5 substituent “down”; and (4) trans with the C2 substituent “down” and the C5 substituent “up”. The two cis enantiomers together are referred to as a racemic mixture of &bgr;-enantiomers, and the two trans enantiomers are referred to as a racemic mixture of &agr;-enantiomers. In general, it is fairly standard to be able to separate the pair of cis racemic optical isomers from the pair of trans racemic optical isomers. It is a significantly more difficult challenge to separate or otherwise obtain the individual enantiomers of the cis-configuration. For 3TC and FTC, the desired stereochemical configuration is the &bgr;-L-isomer.
Routes to Produce the 1,3-Oxathiolane Ring
The numbering scheme for the 1,3-oxathiolane ring is given below.
Kraus, et al., (“Synthesis of New 2,5-Disubstituted 1,3-Oxathiolanes. Intermediates in Nucleoside Chemistry”, Synthesis, pages 1046-1048 (1991)) describe the problems associated with the reaction of an aldehyde of a glyoxylate or glycolic acid with mercaptoacetic acid in toluene in the presence of p-toluenesulfonic acid. Kraus notes that a requirement for the success of this reaction is that glycolic derivatives which exist in the hydrate form have to be converted into the free aldehyde by azeotropic removal of water with toluene before the cyclocondensation. Thereafter, to complete the reduction of both the lactone and carboxylic acid functions, different catalytic reductive reagents had to be employed. Reduction with sodium borohydride failed, and borane-methyl sulfide complex (BMS) was able to reduce only the carboxylic acid function. When the temperature was raised, or a large excess of BMS was used, ring opening occurred leading to polymeric material. Reduction of the 2-carboxy-1,3-oxathiolan-5-one with sodium bis(2-methoxyethoxy)aluminum hydride in toluene gave a mixture of products. Tributyl tin hydride gave no reduction. Finally, when the reduction was performed on the protected lactones, it was not possible to isolate the desired compound, regardless of the catalytic reductive conditions.
Because of these difficulties, Kraus, et al. proposed a reaction that involved the cyclocondensation of anhydrous glyoxylates with 2-mercaptoacetaldehyde diethyl acetal at reflux in toluene to produce 5-ethoxy-1,3-oxathiolane derivatives which could be reduced with BMS to give the corresponding 2-hydroxymethyl-1,3-oxathiolane in 50% yield, which after benzoylation provided a mixture of cis and trans 2-benzoyloxymethyl-5-ethoxy-1,3-oxathiolane. This process is also described in U.S. Pat. No. 5,047,407.
U.S. Pat. No. 5,248,776 discloses a method for the production of enantiomerically pure &bgr;-L-1,3-oxathiolane nucleosides from 1,6-thioanyhydro-L-gulose.
U.S. Pat. No. 5,204,466 discloses a route to prepare the 1,3-oxathiolane ring via the reaction of mercaptoacetic acid (thioglycolic acid) with a glycoaldehyde to form 2-(R-oxy)-methyl-5-oxo-1,3-oxathiolane.
U.S. Pat. No. 5,466,806 describes a process for preparing a 2-hydroxymethyl-5-hydroxy-1,3-oxathiolane via the reaction of the dimer of mercaptoacetaldehyde with a compound of the formula R
w
OCH
2
CHO under neutral or basic conditions, wherein R
w
is a hydroxyl protecting group. See also McIntosh, et al, “2-Mercaptoaldehyde dimers and 2,5-dihydrothiophenes from 1,2-oxathiolan-5-ones,”
Can. J. Chem
. Vol 61, 1872-1875 (1983).
Belleau, et al., disclosed a method to prepare a 1,3-dioxolane nucleoside via the oxidative degradation of L-ascorbic acid. Belleau, et al., “Oxidative Degradation of L-ascorbic Acid Acetals to 2′,3′-Dideoxy-3′-Oxaribofuranosides. Synthesis of Enantiomerically Pure 2′,3′-Dideoxy-3′-Oxacytidine Stereoisomers as Potential Antiviral Agents.,” Tetrahedron Letters, vol 33, No. 46, 6949-6952 (1992).
U.S. Pat. No. 5,204,466 discloses the preparation of a 1,3-oxathiolane ring via ozonolysis of an allyl ether or ester having the formula CH
2
═CHCH
2
OR, in which R is a protecting group, to form a glyco
Almond Merrick R.
Cleary Darryl G.
Liotta Dennis C.
Painter George R.
Soria Josè D.
Emory University
King & Spalding
Knowles, Esq. Sherry M.
McKenzie Thomas C
Shah Mukund J.
LandOfFree
Method of manufacture of 1,3-oxathiolane nucleosides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of manufacture of 1,3-oxathiolane nucleosides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of manufacture of 1,3-oxathiolane nucleosides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3140795